ITCH Trial: Protocol for a Randomized, Double Blind Placebo-controlled Trial
Effectiveness of Intravenous Tranexamic Acid in Primary Cerebral Hemorrhage for Prevention of Hematoma Progression: Protocol for a Randomized, Double Blind Placebo-controlled Trial
Sponsor: Kathmandu Medical College and Teaching Hospital
This PHASE2/PHASE3 trial investigates Cerebral Hemorrhage and is currently completed. Kathmandu Medical College and Teaching Hospital leads this study, which shows 9 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Apr 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Jan 2025 — Apr 2025 [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Jan 2025 [monthly]
Completed PHASE2/PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
▶ Show 4 earlier versions
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting · Phase: EARLY_PHASE1 → PHASE2_PHASE3
-
Nov 2023 — Feb 2024 [monthly]
Recruiting EARLY_PHASE1
Status: Unknown Status → Recruiting
-
Mar 2023 — Nov 2023 [monthly]
Unknown Status EARLY_PHASE1
Status: Not Yet Recruiting → Unknown Status
-
Mar 2021 — Mar 2023 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Feb 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kathmandu Medical College and Teaching Hospital
For direct contact, visit the study record on ClinicalTrials.gov .